Nancy Geller | Academic Influence

Nancy Geller's AcademicInfluence.com Rankings

Nancy Geller

Mathematics

#5334

World Rank

#7512

Historical Rank

Statistics

#596

World Rank

#677

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Nancy Geller's Degrees

Bachelors Mathematics University of Maryland, College Park

Similar Degrees You Can Earn

Best Online Bachelor's in Math 2025

Why Is Nancy Geller Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Marilyn Nancy Lorch Geller is an American biostatistician, the director of biostatistics research at the National Heart, Lung, and Blood Institute and a former president of the American Statistical Association.

(See a Problem?)

Nancy Geller's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study (2004) (1203)
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. (2004) (1095)
Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. (2014) (722)
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse (1989) (677)
A pharmacogenetic versus a clinical algorithm for warfarin dosing. (2013) (667)
Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. (1987) (635)
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. (1985) (623)
Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. Improvement of cardiac ischemia at 1 year after PTCA and CABG. (1995) (580)
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. (2016) (530)
The analysis of multiple endpoints in clinical trials. (1987) (512)
Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. (1997) (477)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. (2017) (414)
Detecting Acute Coronary Syndrome in the Emergency Department With Cardiac Magnetic Resonance Imaging (2003) (370)
Surgical ablation of atrial fibrillation during mitral-valve surgery. (2015) (334)
Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. (2006) (319)
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. (1993) (312)
Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. (1999) (286)
Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. (1983) (281)
Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial (2000) (266)
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. (1990) (263)
Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993--the perspective of NIH clinical trialists. (1995) (259)
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. (2011) (248)
Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. (1996) (239)
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. (1985) (230)
A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. (1988) (225)
Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. (1987) (208)
Lipid-associated sialic acid test for the detection of human cancer. (1982) (194)
Carcinoma of major salivary glands. Recent trends. (1989) (193)
Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. (1984) (188)
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. (2020) (187)
VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. (1986) (183)
Asymptomatic Cardiac Ischemia Pilot (ACIP) study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. The ACIP Investigators. (1995) (179)
The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. (1999) (179)
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. (2008) (178)
Isochromosome of Chromosome 12: Clinically Useful Marker for Male Germ Cell Tumors (1989) (159)
Cytogenetic and molecular analysis of human male germ cell tumors: Chromosome 12 abnormalities and gene amplification (1990) (151)
Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes (2016) (148)
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. (2019) (145)
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial (2000) (135)
Prognostic factors in advanced ovarian carcinoma. (1986) (132)
Salvage chemotherapy for patients with germ cell tumors. The memorial sloan‐kettering cancer center experience (1979–1989) (1991) (131)
Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy (1991) (130)
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduce (2019) (127)
Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. (1996) (125)
Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. (1990) (124)
Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. (1988) (124)
Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators. (2000) (124)
Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study. (1994) (123)
Management practices and major infections after cardiac surgery. (2014) (121)
Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy. (2015) (116)
The Asymptomatic Cardiac Ischemia Pilot (ACIP) study: design of a randomized clinical trial, baseline data and implications for a long-term outcome trial. (1994) (114)
Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. (1999) (112)
An approximate likelihood ratio test for a normal mean vector with nonnegative components with application to clinical trials (1989) (109)
Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival (1982) (108)
On the design and analysis of randomized clinical trials with multiple endpoints. (1993) (108)
Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. (2019) (107)
Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy (1985) (106)
The role of ifosfamide plus cisplatin‐based chemotherapy as salvage therapy for patients with refractory germ cell tumors (1990) (104)
Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial (2010) (101)
Overcoming graft rejection in heavily transfused and allo‐immunised patients with bone marrow failure syndromes using fludarabine‐based haematopoietic cell transplantation (2006) (99)
Monitoring pairwise comparisons in multi-armed clinical trials. (1994) (98)
Charting a roadmap for heart failure biomarker studies. (2014) (95)
Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features (1991) (91)
Testing association for markers on the X chromosome (2007) (89)
Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. (1985) (88)
Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. (1999) (87)
Design of Group Sequential Clinical Trials with Multiple Endpoints (1989) (85)
Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. (1998) (81)
Improved survival in steroid‐refractory acute graft versus host disease after non‐myeloablative allogeneic transplantation using a daclizumab‐based strategy with comprehensive infection prophylaxis (2004) (77)
A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)‐Fc fusion protein in patients with myelodysplastic syndrome (2002) (74)
Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. (2014) (73)
Nephrotic syndrome: an under‐recognised immune‐mediated complication of non‐myeloablative allogeneic haematopoietic cell transplantation (2005) (73)
Diabetics with coronary disease have a prevalence of asymptomatic ischemia during exercise treadmill testing and ambulatory ischemia monitoring similar to that of nondiabetic patients. An ACIP database study. ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot Investigators. (1996) (71)
Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901 (2015) (71)
Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. (1990) (70)
Pancreaticoduodenectomy: A 40‐Year Experience (1982) (70)
After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer. (1994) (69)
Advanced seminoma: the role of chemotherapy and adjunctive surgery. (1988) (68)
Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. (2005) (68)
Effect of an Aggressive Lipid-Lowering Strategy on Progression of Atherosclerosis in the Left Main Coronary Artery From Patients in the Post Coronary Artery Bypass Graft Trial (2001) (65)
Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. (1987) (65)
Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. (2000) (64)
Closed Testing Procedures for Group Sequential Clinical Trials with Multiple Endpoints (1999) (64)
Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. (2005) (64)
Pancreaticoduodenectomy for Benign Disease (1983) (63)
Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud. (2000) (62)
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis. (2021) (62)
Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study (2019) (61)
Treatment for Mild Chronic Hypertension during Pregnancy. (2022) (61)
Both Light Intensity and Moderate‐to‐Vigorous Physical Activity Measured by Accelerometry Are Favorably Associated With Cardiometabolic Risk Factors in Older Women: The Objective Physical Activity and Cardiovascular Health (OPACH) Study (2017) (59)
Patient‐reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902) (2016) (57)
Serum tumor markers in patients with metastatic germ cell tumors of the testis. A 10-year experience. (1983) (56)
Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. (2004) (55)
Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone‐refractory prostatic cancer treated with single‐agent chemotherapy (1992) (53)
Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators (2005) (53)
Design of phase I and II clinical trials in cancer: a statistician's view. (1984) (51)
Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors (1989) (50)
Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial (2016) (45)
Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). (2020) (44)
Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. (2008) (44)
Relation between clinical, angiographic and ischemic findings at baseline and ischemia-related adverse outcomes at 1 year in the Asymptomatic Cardiac Ischemia Pilot study. ACIP Study Group. (1997) (44)
Fraud in medical research. (2000) (43)
Rationale and study design of the CardioGene Study: genomics of in-stent restenosis. (2004) (42)
Ischemia during ambulatory monitoring as a prognostic indicator in patients with stable coronary artery disease. (1997) (41)
Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. (1993) (40)
Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] Study). (1996) (40)
Stage migration and the increasing proportion of complete responders in patients with advanced germ cell tumors. (1988) (38)
Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover. (1987) (35)
Endotoxin‐induced in vitro release of interleukin‐1 by cancer patients' monocytes: Relation to stage of disease (1983) (33)
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. (2021) (33)
Monitoring multi-armed trials. (1994) (32)
Two‐drug therapy in patients with metastatic germ cell tumors (1991) (31)
The effect of unrelated donor marrow transplantation on health-related quality of life: a report of the unrelated donor marrow transplantation trial (T-cell depletion trial). (2006) (31)
Differences in the Phenotype, Cytokine Gene Expression Profiles, and In Vivo Alloreactivity of T Cells Mobilized with Plerixafor Compared with G-CSF (2013) (30)
Carboplatin, etoposide, and bleomycin for patients with poor‐risk germ cell tumors (1990) (29)
Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial (2010) (27)
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study (2012) (26)
A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers (2011) (26)
Isochromosome of the short arm of chromosome 12: clinically useful markers for male germ cell tumors. (1989) (26)
Impact of symptomatic interval on prognosis of patients with stage III testicular cancer. (1983) (25)
Robust Tests in Genome-Wide Scans under Incomplete Linkage Disequilibrium (2009) (25)
Advances in Clinical Trial Biostatistics (2003) (25)
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. (2019) (25)
Vinblastine and methotrexate for advanced bladder cancer. (1985) (25)
Practical issues in data monitoring of clinical trials: summary of responses to a questionnaire at NIH. (1993) (24)
Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function. (2008) (24)
Secondary surgical‐site infection after coronary artery bypass grafting: A multi‐institutional prospective cohort study (2017) (23)
Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials (2007) (23)
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies (2021) (23)
Change in Physical Activity and Sitting Time After Myocardial Infarction and Mortality Among Postmenopausal Women in the Women's Health Initiative‐Observational Study (2017) (22)
Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study (2019) (22)
Current challenges for clinical trials of cardiovascular medical devices. (2014) (22)
Identification and management of poor risk patients with germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. (1988) (22)
The effect of a 7‐day delay in chemotherapy cycles on complete response and event‐free survival in good‐risk disseminated germ cell tumor patients (1990) (22)
Sample size calculation for clinical trials in which entry criteria and outcomes are counts of events (1994) (21)
Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors. (1991) (21)
Limited access data sets from studies funded by the National Heart, Lung, and Blood Institute (2004) (21)
Angiographic changes in saphenous vein grafts are predictors of clinical outcomes. (2003) (20)
Prognostic factors in metastatic germ cell tumors. (1990) (20)
Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria. (2014) (20)
Robust ranks of true associations in genome-wide case-control association studies (2007) (19)
Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer. (1985) (19)
Negative Epistasis between Sickle and Foetal Haemoglobin Suggests a Reduction in Protection against Malaria (2015) (19)
Conversations with NIH statisticians: interviews with the pioneers of biostatistics at the United States National Institute of Health (1997) (19)
Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis (1983) (19)
When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches (2012) (19)
Non-myeloablative allogeneic stem cell transplantation (NST) for metastatic melanoma: nondurable chemotherapy responses without clinically meaningful graft-vs-tumor (GVT) effects. (2002) (18)
Coronary Artery Calcification (CAC) and Post‐Trial Cardiovascular Events and Mortality Within the Women's Health Initiative (WHI) Estrogen‐Alone Trial (2017) (18)
Designing comparative effectiveness trials of surgical ablation for atrial fibrillation: experience of the Cardiothoracic Surgical Trials Network. (2011) (18)
Use of biological assignment in hematopoietic stem cell transplantation clinical trials (2008) (18)
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? (2012) (18)
Sensitivity analysis using an imputation method for missing binary data in clinical trials (2001) (18)
On the choice of times for data analysis in group sequential clinical trials. (1991) (18)
Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer. (1988) (17)
Biomarker-guided therapies in heart failure: a forum for unified strategies. (2013) (17)
Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. (1999) (16)
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. (2013) (16)
Association of disease‐free survival and percent of ideal dose in adjuvant breast chemotherapy (1990) (16)
Interim Analyses in Randomized Clinical Trials (1986) (16)
Surrogate endpoints in randomized cardiovascular clinical trials (2011) (15)
Serum tumor markers and patient allocation to good‐risk and poor‐risk clinical trials in patients with germ cell tumors (1991) (15)
Interpreting tests for efficacy in clinical trials with multiple endpoints. (1997) (15)
Meta-analysis of clinical trials: a consumer's guide. (1996) (15)
When should data and safety monitoring committees share interim results in cardiovascular trials? (2008) (15)
Monitoring a general class of two-sample survival statistics with applications (1999) (14)
Neural modulation for hypertension and heart failure. (2016) (14)
Statistics: An All-Encompassing Discipline (2011) (14)
Randomized Study of Intrahepatic vs Systemic Infusion of Fluorodeoxyuridine in Patients with Liver Metastases from Colorectal Carcinoma (Preliminary Results) (1984) (13)
Conference on meta-analysis in the design and monitoring of clinical trials. (1999) (13)
Implementation of the Group Sequential Methodology in a Randomized Trial in Metastatic Colorectal Carcinoma (1988) (13)
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT) (2022) (12)
Risk Factor Burden, Heart Failure, and Survival in Women of Different Ethnic Groups: Insights From the Women’s Health Initiative (2018) (12)
Planned interim analysis and its role in cancer clinical trials. (1987) (12)
Discussion of ‘interim analysis: The alpha spending approach’ (1994) (11)
Umbilical cord blood transplantation in pediatric patients: Results of the prospective, multi-institutional Cord Blood Transplantation Study (COBLT) (2006) (11)
Erratum: A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome (British Journal of Haematology 117 (119-126)) (2002) (10)
Stochastic curtailing and conditional power in matched case-control studies. (1994) (10)
Serum Tumor Markers in Patients With Metastatic Germ Cell Tumors of the Testis (1984) (10)
Selection of single-nucleotide polymorphisms in disease association data (2005) (10)
Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer? (1990) (10)
Smart Technology in Lung Disease Clinical Trials. (2016) (10)
Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902 (2014) (9)
Cooperative Heart Disease Trials Sponsored by the National Heart, Lung, and Blood Institute (NHLBI) (2016) (9)
An extension of stochastic curtailment for incompletely reported and classified recurrent events: the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH). (1997) (9)
Industry, Government, and Academic Panel Discussion on Multiple Comparisons in a “Real” Phase Three Clinical Trial (2003) (9)
Phase II trial of 4'-deoxydoxorubicin in patients with advanced breast cancer. (1985) (9)
Robust genome-wide scans with genetic model selection using case-control design ∗ (2009) (8)
Introduction to the Special Issue: Genome-Wide Association Studies (2009) (8)
Predictors of Major Atrial Fibrillation Endpoints in the National Heart, Lung, and Blood Institute HCMR. (2021) (8)
On Averaging Power for Genetic Association and Linkage Studies (2005) (8)
Clinical Evaluation of Anticancer Treatments: Phase II Clinical Trials (1987) (8)
An application of the Zucker-Wittes modified ratio estimate statistic in the Post Coronary Artery Bypass Graft (CABG) clinical trial. (1997) (7)
Anginal status and prediction of cardiac events in patients enrolled in the asymptomatic cardiac ischemia pilot (ACIP) study. ACIP investigators. (1997) (7)
Time course analysis of gene expression identifies multiple genes with differential expression in patients with in-stent restenosis (2011) (7)
Joint analysis of case-parents trio and unrelated case-control designs in large scale association studies (2007) (7)
Genotype-guided dosing of vitamin K antagonists. (2014) (7)
Design of Phase I and II Trials in Cancer (1990) (7)
Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry (2020) (7)
Evaluation of Three Different Cyclosporine-Based Graft Versus Host Disease (GVHD) Prophylaxis Regimens Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST). (2004) (6)
Significant Alterations in T-Cell TH1 and TH2 Cytokine Gene Profiles Associated with G-CSF Mobilization Do Not Occur in T-Cells Mobilized with AMD3100. (2007) (6)
Overview of the DIG trial. (2003) (6)
Factors Associated With New‐Onset Depression Following Ischemic Stroke: The Women's Health Initiative (2017) (6)
Systemic absorption of a leucovorin mouth wash: a pharmacologic study. (1987) (5)
Assessment of risk in metastatic testis carcinoma: impact on treatment. (1991) (5)
Phase II trial of mitoguazone in patients with advanced head and neck cancer. (1984) (5)
Implementing family-based behavioral treatment in the pediatric primary care setting: Design of the PLAN study. (2021) (5)
The NHLBI Post-Coronary Artery Bypass Graft Clinical Trial (Post-CABG): angiographic outcomes (1996) (5)
Rapid donor T‐cell engraftment increases the risk of chronic graft‐versus‐host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes (2013) (5)
Asymptomatic cardiac ischemia pilot (ACIP). (1995) (5)
Relation Between Clinical, Angiographic and Ischemic Findings at Baseline and Ischemia-Related Adverse Outcomes at 1 Year in the Asymptomatic Cardiac Ischemia Pilot Study (2016) (4)
testing treatment efficacy in clinical trials with repeated binary measurements and missing observations (1994) (4)
Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Results of the BMT CTN 1301 Progress II Trial (2021) (3)
Simple strategies for haplotype analysis of the X chromosome with application to age-related macular degeneration (2011) (3)
MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial. (2021) (3)
Phase II trial of N-methylformamide in patients with advanced colorectal carcinoma. (1986) (3)
Chemotherapeutic management of invasive bladder carcinoma. (1988) (3)
A Pilot Study Evaluating the CD34+ Cell Mobilizing Activity and Adverse Events Associated with Escalating Doses of AMD3100 in Healthy Volunteers. (2007) (3)
Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome (2021) (3)
Analysis of chromosome 12 abnormalities in male germ cell cancers. (1991) (3)
Response to discussants' letters (1995) (3)
Relation of patient characteristics to cardiac ischemia during daily life activity (an Asymptomatic Cardiac Ischemia Pilot Data Bank Study). (1996) (3)
Design of Early Trials in Stem Cell Transplantation: A Hybrid Frequentist-Bayesian Approach* (2003) (2)
Longitudinal clinical trials with adaptive choice of follow‐up time (2015) (2)
NHLBI clinical trials workshop: an executive summary (2012) (2)
Lessons learned from the DIG trial. (2003) (2)
Identifying high yield sources of patients with coronary artery disease for clinical trials: Lessons from the asymptomatic cardiac ischemia pilot (ACIP) experience (1998) (2)
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma (2022) (2)
Design and Analysis of Clinical Trials with Multiple Endpoints (2003) (2)
Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401) (2021) (2)
Monitoring Randomized Clinical Trials (2012) (2)
The Influence of Biostatistics at the National Heart, Lung, and Blood Institute (2015) (2)
Issues in the analysis of clinical trials for opiate dependence. (1992) (2)
Reduced Incidence of Acute Graft Versus Host Disease (GVHD) and Transplant-Related Mortality (TRM) with the Addition of Short-Course Mini-Dose Methotrexate (MTX) to Cyclosporine (CSA) as GVHD Prophylaxis Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST). (2007) (1)
The future of clinical trials: A panel discussion (2012) (1)
Role of meta-analyses in design and monitoring of randomized clinical trials : Summary of first day of the workshop (1996) (1)
E ffects of Aggressive Cholesterol Lowering and Low-Dose Anticoagulation on Clinical and Angiographic Outcomes in Patients With Diabetes The Post Coronary Artery Bypass Graft Tr i a l (1999) (1)
Some Examples of the Weak and Strong Laws of Large Numbers for Averages of Mutually Independent Random Variables (1978) (1)
Abstract 3689: Genome Wide Association Study of In-stent Restenosis Identifies Multiple Candidate Susceptibility Loci (2006) (1)
A conversation with Tavia Gordon (1997) (1)
Group Sequential Monitoring of Multi-Armed Clinical Trials (1995) (1)
Group Sequential Monitoring of Multi-Armed Clinical Trials (1995) (1)
A Randomized Trial of Etoposide + Cisplatin Versus Vinblastine + Bleomycin + Cisplatin + Cyclophosphamide + Dactinomycin in Patients with Good-Prognosis Germ Cell Tumors (1989) (1)
Design of Early Trials in Stem Cell Transplantation (2003) (1)
High Response Rates in Acute Steroid Refractory Graft-Versus-Host Disease (GVHD) Following Combined Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-2 (IL-2) Blockade. (2005) (1)
Commentary on ‘Redesign of trials under different enrolment mixes’ by Curtis L. Meinert (1999) (1)
Coping with Information Loss and the Use of Auxiliary Sources of Data: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions (2022) (1)
Delayed progression of atherosclerosis in coronary bypass grafts is similar in women compared to men following aggressive cholesterol lowering despite more frequent risk factors: post CABG trial (1998) (1)
Exercise and Stress Management Training For Patients Undergoing Autologous Or Allogeneic Hematopoietic Cell Transplantation. Results From Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902 (2013) (1)
Biologic Assignment Clinical Trials in Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Myeloma: Baseline Characteristics by Treatment Allocation from BMT CTN 0102 According to Availability of an HLA-Matched Sibling Donor. (2007) (0)
Prevention of graft versus host disease with Hematopoietic CellTransplantation with Reduced Intensity Conditioning—a comparison of threeprophylaxis regimens (tacrolimus/mycophenolate mofetil/cyclophosphamide,tacrolimus/methotrexate/bortezomib or tacrolimus/methotrexate/maraviroc) versustacrolimus/me (2019) (0)
Detecting treatment differences in group sequential longitudinal studies with covariate adjustment (2018) (0)
A59 An extension of stochastic curtailment for incompletely reported and classified data on recurrent outcomes: The multicenter study of hydroxyurea in sickle cell anemia (MSH) (1996) (0)
A Conversation with Robert C. Elston (2015) (0)
Letter to the Editor (2005) (0)
Letter to the editorLetter to the editor (2001) (0)
Absence of Graft Failure and Excellent Long Term Survival Following Fludarabine-Based Reduced Intensity Hematopoietic Stem Cell Transplantation In Heavily Transfused Patients with ATG-Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes (2010) (0)
Sample size calculation for clinical trials in which entry criteria and outcomes are counts of events. ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot. (1994) (0)
On the design and analysis of randomized clinical trials with multiple end-points (1991) (0)
Pragmatic Clinical Trials (2019) (0)
Discussion of “A Hybrid Phase I‐II/III Clinical Trial Design Allowing Dose Re‐Optimization in Phase III” by Andrew G. Chapple and Peter F. Thall (2019) (0)
CARDIOTHORACIC SURGICAL EDUCATION AND (2011) (0)
The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302). (2021) (0)
Cooperative Heart Disease Trials (2005) (0)
Abstract 16702: Myocardial Deformation Analysis in Hypertrophic Cardiomyopathy With Sarcomere Mutations: Insights From 2,221 Patients Within the NHLBI-HCM Registry (2020) (0)
Food and Drug Administration Center for Drug Evaluation and Research Summary Minutes of the Gastrointestinal Drugs Advisory Committee (2001) (0)
Distinct Subgroups in Hypertrophic Cardiomyopathy: Baseline Results From HCMR (2019) (0)
Nephrotic syndrome associated with thrombotic microangiopathy following allogeneic stem cell transplantation for myelodysplastic syndrome – response to Nakamura et al (2007) (0)
Basic principles of clinical trials as applied to testicular cancer. (1990) (0)
An analysis of poor risk assignment in patients with germ cell tumours. (1987) (0)
Pre-Transplant T-Cell Lymphopenia Accelerates Early Donor T-Cell and Myeloid Chimerism but Is Not Required for Full Donor Lymphohematopoietic Engraftment or To Prevent Graft Rejection Following Nonmyeloablative Hematopoietic Cell Transplantation (NST). (2006) (0)
Combined tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2) blockade in acute steroid refractory graft-versus-host disease (SR-GVHD) following allogeneic hematopoietic stem cell transplantation (HCT). (2009) (0)
Issues of protocol modification after initiation of a large multi-center trial (1998) (0)
In memoriam: Gang Zheng (May 6, 1965 – January 9, 2014) (2014) (0)
Early Positive Biopsy in Asymptomatic Post-Allogenic Hematopoietic Stem Cell Transplant Recipients Is Not Associated with the Development of Clinical Chronic Graft-Versus-Host Disease (2019) (0)
Author's response to reviews Title: Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial Authors: Benjamin French (bcfrench@upenn.edu) (2010) (0)
Transitioning a randomized controlled trial to a digital registry – experience from the TAILOR-PCI digital follow-up study on onboarding, engagement and geofencing consent rate (2020) (0)
Implementing Digital Technology to Transitioning a Clinical Trial to a Registry – TAILOR-PCI Digital Study: Methods/Study Design (Preprint) (2021) (0)
Abstract 2874: Sudden Cardiac Death in Patients with Stable Coronary Disease and Preserved Left Ventricular Systolic Function (2007) (0)
Adaptive Two-Stage Clinical Trials* (2003) (0)
Comments on "Efficacy of Urinalysis in Monitoring Heroin and Cocaine Abuse Patterns: Implications in Clinical Trials for Treatment of Drug Dependence" by Cone and Dickerson: (496082006-011) (1992) (0)
Associated Risk Factors do Not Prevent the Beneficial Effect of Aggressive Cholesterol Lowering: Post CABG Trial (1998) (0)
Long-Term Follow-up of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Severe Paroxysmal Nocturnal Hemoglobinuria (2010) (0)
Rare loss of function variants in candidate genes and risk of colorectal cancer (2018) (0)
Robust Association Tests for the Replication of Genome-Wide Association Studies (2015) (0)
Abstract # 1729 Psychosocial and socioeconomic status as predictors of outcomes following hematopoietic stem cell transplantation: An ancillary study from the BMT CTN 0902 randomized controlled trial (RCT) (2016) (0)
Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance (2017) (0)
Clinical trials and epidemiological studies. (2005) (0)
PREDICTORS OF CLINICALLY SIGNIFICANT ATRIAL FIBRILLATION IN THE NHLBI HYPERTROPHIC CARDIOMYOPATHY REGISTRY (HCMR) (2020) (0)
Evaluating treatment effects in group sequential multivariate longitudinal studies with covariate adjustment. (2022) (0)
Abstract 6785: Dendritic cell/myeloma fusion vaccine with lenalidomide maintenance following autologous hematopoietic cell transplant induced T cell activation and expansion (2023) (0)
Description of angiographic outcome measures to evaluate changes in coronary grafts: the NHLBI post coronary artery bypass graft (POST CABG) clinical trial (1994) (0)
Discussion on “Quantifying Publication Bias in Meta‐Analysis” by Lin and Chu (2018) (0)
2012 Publications of the Baylor Health Care System Medical and Scientific Staff (2013) (0)
Discussion on “Second-Guessing Clinical Trial Designs” by Jonathan J. Shuster and Myron N. Chang (2008) (0)

This paper list is powered by the following services:

Other Resources About Nancy Geller

en.wikipedia.org

What Schools Are Affiliated With Nancy Geller?

Nancy Geller is affiliated with the following schools: